NCT05954143Phase 2Terminated

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Study sponsor: Bolt Biotherapeutics, Inc. · BOLT

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-09-20Actual

Enrollment · participants11Actual

Source updated2025-11-20Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Metastatic Breast Cancer; HER2-positive Breast Cancer

Treatments or interventions studied

BDC-1001Drug
PertuzumabDrugAlso known as Perjeta®

Primary outcomes · main study measures

measure: Objective Response Rate (ORR) Per RECIST v1.1 as Assessed by Investigator; description: Objective Response Rate (ORR) was defined as the proportion of participants with best overall response of confirmed Complete Response (CR) or Partial Response (PR) as determined by the treating Investigator using RECIST v1.1 criteria.; timeFrame: Up to approximately 1 year

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history